Medicare and its beneficiaries are paying significantly more for Stelara, Johnson & Johnson’s (NYSE:JNJ) popular biologic drug used to treat autoimmune diseases when obtained through pharmacies rather ...

Please provide your email address to receive an email when new articles are posted on . Selarsdi is approved for the treatment of plaque psoriasis, psoriatic arthritis in adults, patients aged 6 years ...

Teva Pharmaceuticals and Alvotech have announced that the US Food and Drug Administration (FDA) has approved the Selarsdi (ustekinumab-aekn) injection as interchangeable with reference biologic ...

Fresenius Kabi, an Operating Company of Fresenius, and a leading provider of essential medicines and medical technologies, ...

Please provide your email address to receive an email when new articles are posted on . Four biosimilars for Stelara have launched in the United States this year following legal settlements with the ...

The Food and Drug Administration has approved Celltrion's Steqeyma (ustekinumab-stba), a biosimilar to Johnson & Johnson's Stelara (ustekinumab), for subcutaneous injection or intravenous infusion in ...

Stelara (ustekinumab) is a prescription drug that treats autoimmune conditions such as plaque psoriasis. You typically inject it subcutaneously (under your skin) or receive it intravenously (directly ...

55.2 percent of induction responder patients treated with STELARAat the start of maintenance were in symptomatic remission approximately four years later (at week 200), 96.4 percent without ...